PAZOPANIB HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
When do Pazopanib Hydrochloride patents expire, and what generic alternatives are available?
Pazopanib Hydrochloride is a drug marketed by Apotex, Novugen, Sun Pharm, and Teva Pharms Inc. and is included in four NDAs.
The generic ingredient in PAZOPANIB HYDROCHLORIDE is pazopanib hydrochloride. There are five drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the pazopanib hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Pazopanib Hydrochloride
A generic version of PAZOPANIB HYDROCHLORIDE was approved as pazopanib hydrochloride by APOTEX on October 19th, 2023.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for PAZOPANIB HYDROCHLORIDE?
- What are the global sales for PAZOPANIB HYDROCHLORIDE?
- What is Average Wholesale Price for PAZOPANIB HYDROCHLORIDE?
Summary for PAZOPANIB HYDROCHLORIDE
| US Patents: | 0 |
| Applicants: | 4 |
| NDAs: | 4 |
| Finished Product Suppliers / Packagers: | 6 |
| Raw Ingredient (Bulk) Api Vendors: | 102 |
| Clinical Trials: | 285 |
| Patent Applications: | 518 |
| DailyMed Link: | PAZOPANIB HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for PAZOPANIB HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University Medical Center Groningen | Phase 4 |
| Alliance for Clinical Trials in Oncology | Phase 2/Phase 3 |
| Shenzhen Chipscreen Biosciences Co.Ltd | Phase 2 |
Pharmacology for PAZOPANIB HYDROCHLORIDE
| Drug Class | Kinase Inhibitor |
| Mechanism of Action | Cytochrome P450 2C8 Inhibitors Cytochrome P450 2D6 Inhibitors Cytochrome P450 3A4 Inhibitors Protein Kinase Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for PAZOPANIB HYDROCHLORIDE
US Patents and Regulatory Information for PAZOPANIB HYDROCHLORIDE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apotex | PAZOPANIB HYDROCHLORIDE | pazopanib hydrochloride | TABLET;ORAL | 217713-001 | Oct 19, 2023 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Teva Pharms Inc | PAZOPANIB HYDROCHLORIDE | pazopanib hydrochloride | TABLET;ORAL | 217517-001 | Oct 19, 2023 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Novugen | PAZOPANIB HYDROCHLORIDE | pazopanib hydrochloride | TABLET;ORAL | 218231-001 | Apr 23, 2024 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Sun Pharm | PAZOPANIB HYDROCHLORIDE | pazopanib hydrochloride | TABLET;ORAL | 215837-001 | Oct 19, 2023 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
